Imagion Biosystems Ltd. engages in the research and development of non-radioactive and safe diagnostic imaging technology. It offers MagSense technology which does not use ionizing radiation, radioactive tracers, or strong magnetic fields; and PrecisionMRX nanoparticles, which is used for magnetic relaxometry and other biomedical applications where the magnet susceptibility of the nanoparticle can be instrumental. The company was founded by Edward R. Flynn on December 6, 2016 and is headquartered in Melbourne, Australia.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company